Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
Sponsor: Ocugenix Corporation
Summary
Multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-10-C-110 for Injection in the study eye of participants with nAMD
Official title: Safety and Tolerability of Single Ascending Doses and Multiple Repeat Doses of OCU-10-C-110 for Injection in Study Participants With Neovascular Age-related Macular Degeneration (nAMD)
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
19
Start Date
2023-11-01
Completion Date
2026-11-30
Last Updated
2025-03-21
Healthy Volunteers
No
Interventions
OCU-10-C-110 for Injection
OCU-10-C-110 for Injection in one of 3 doses
Locations (3)
Raj K. Maturi, M.D., P.C.
Carmel, Indiana, United States
Retina Research Institute of Texas
Abilene, Texas, United States
Strategic Clinical Research Group LLC
Willow Park, Texas, United States